Multivalent Targeting of the Asialoglycoprotein Receptor by Virus‐Like Particles
Small · 2023-12 · 19 (52)
DOI: 10.1002/smll.202304263 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 30.08.2023. Verfasst von Robert Hincapie und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Biochemistry, Georgia Institute of Technology, 901 Atlantic Drive, Atlanta, GA, 30332, USA. Hauptthemen laut MEDLINE: Endothelial Cells, Liver. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Pfizer.
Abstract (Originalsprache)
The asialoglycoprotein receptor (ASGPR) is expressed in high density on hepatocytes. Multivalent variants of galactosyl carbohydrates bind ASGPR with high affinity, enabling hepatic delivery of ligand‐bound cargo. Virus‐like particle (VLP) conjugates of a relatively high‐affinity ligand were efficiently endocytosed by ASGPR‐expressing cells in a manner strongly dependent on the nature and density of ligand display, with the best formulation using a nanomolar‐, but not a picomolar‐level, binder. Optimized particles were taken up by HepG2 cells with greater efficiency than competing small molecules or the natural multigalactosylated ligand, asialoorosomucoid. Upon systemic injection in mice, these VLPs were rapidly cleared to the liver and were found in association with sinusoidal endothelial cells, Kupffer cells, hepatocytes, dendritic cells, and other immune cells. Both ASGPR‐targeted and nontargeted particles were distributed similarly to endothelial and Kupffer cells, but targeted particles were distributed to a greater number and fraction of hepatocytes. Thus, selective cellular trafficking in the liver is difficult to achieve: even with the most potent ASGPR targeting available, barrier cells take up much of the injected particles and hepatocytes are accessed only approximately twice as efficiently in the best case.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Biochemistry, Georgia Institute of Technology, 901 Atlantic Drive, Atlanta, GA, 30332, USA.
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory School of Medicine, 313 Ferst Dr NW, Atlanta, GA, 30332, USA.
- School of Biological Sciences, Georgia Institute of Technology, 901 Atlantic Drive, Atlanta, GA, 30332, USA.
ORCID-Profile: M G Finn
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- Pfizer
Zitieren
APA
Hincapie, R., Bhattacharya, S., Baksh, M. M., Sanhueza, C. A., Echeverri, E. S., Kim, H., Paunovska, K., Podilapu, A. R., Xu, M., Dahlman, J. E., & Finn, M. G. (2023). Multivalent Targeting of the Asialoglycoprotein Receptor by Virus‐Like Particles. Small, 19(52). https://doi.org/10.1002/smll.202304263
Vancouver
Hincapie R, Bhattacharya S, Baksh MM, Sanhueza CA, Echeverri ES, Kim H, et al. Multivalent Targeting of the Asialoglycoprotein Receptor by Virus‐Like Particles. Small. 2023;19(52). doi:10.1002/smll.202304263
BibTeX
@article{Hincapie2023,
author = {Hincapie, Robert and Bhattacharya, Sonia and Baksh, Michael M and Sanhueza, Carlos A and Echeverri, Elisa Schrader and Kim, Hyejin and Paunovska, Kalina and Podilapu, Ananda R and Xu, Minghao and Dahlman, James E and Finn, M G},
title = {Multivalent Targeting of the Asialoglycoprotein Receptor by Virus‐Like Particles},
journal = {Small},
year = {2023},
volume = {19},
number = {52},
doi = {10.1002/smll.202304263}
}
EUVIMED